West Pharmaceutical Services launches new admixture device

23 October 2020 (Last Updated October 23rd, 2020 11:53)

West Pharmaceutical Services has announced receipt of the Food and Drug Administration (FDA) 510(k) clearance and the launch of its Vial2Bag Advanced 20mm Admixture Device.

West Pharmaceutical Services launches new admixture device
West’s Vial2Bag Advanced 20mm Admixture Device is designed to enable the reconstitution and transfer of a drug between a vial and an IV bag. Credit: Marcelo Leal / Unsplash.

West Pharmaceutical Services has announced receipt of the Food and Drug Administration (FDA) 510(k) clearance and the launch of its Vial2Bag Advanced 20mm Admixture Device.

The new device is designed to enable the reconstitution and transfer of a drug between a vial and an IV bag.

It features both a dual-channel design to offer dedicated fluid pathways into and out of the IV bag. Additionally, it has a vial spike design, which enhances the connection to the drug vial.

Furthermore, the new admixture device is needle-free, in accordance with OSHA and NAPPSI sharps prevention guidance.

The device is also a simple solution for just-in-time IV medication preparation, enhancing the efficiency of point-of-care nursing.

It also helps to reduce drug and IV fluid waste by offering universal compatibility with all manufacturers’ IV bags up to 250ml. It is also suitable for use with liquid and powder medications with standard 20mm closure vials.

West Commercial Products and Solutions senior vice-president Cindy Reiss-Clark said: “The development of our Vial2Bag Advanced device is a true example of our ongoing commitment to product development and point-of-care delivery.

“This solution is needed now more than ever in the current healthcare climate, and West is pleased to bring this innovation to the market.”

West Pharmaceutical Service specialises in the manufacturing of packaging components and delivery systems for injectable drugs and healthcare products.

The company said it recorded net sales worth $1.84bn last year.